Hot Features
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist ... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.14 | 3.80634390651 | 29.95 | 32.2 | 28.46 | 394568 | 30.13623535 | CS |
| 4 | -0.18 | -0.575631595779 | 31.27 | 33.33 | 28.33 | 363889 | 30.14007161 | CS |
| 12 | 4.56 | 17.1880889559 | 26.53 | 33.33 | 24.95 | 296097 | 29.29654602 | CS |
| 26 | 3.49 | 12.6449275362 | 27.6 | 33.33 | 23.15 | 242185 | 27.90452791 | CS |
| 52 | 14.48 | 87.1763997592 | 16.61 | 33.33 | 15.91 | 230908 | 26.02344182 | CS |
| 156 | 22.32 | 254.503990878 | 8.77 | 33.33 | 8.2 | 131136 | 23.93490672 | CS |
| 260 | 10.66 | 52.1781693588 | 20.43 | 33.33 | 1.77 | 192160 | 16.00913697 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.